Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation

Epilepsy and Behavior

Volumn 4, Issue 4, 2003, Pages 386-394

  McKee, Jerry R ^a   Sunder, T R ^b   FineSmith, R ^c   Vuong, A ^d   Varner, J A ^d   Hammer, A E ^d   Barrett, P S ^d  

^a Western Carolina Center   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Epilepsy; Lamotrigine; Mental retardation

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGGRESSION; AGITATION; ANOREXIA; ARTICLE; ATAXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EATING DISORDER; EPILEPSY; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HOSTILITY; HUMAN; IRRITABILITY; LETHARGY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MENTAL INSTABILITY; MOTOR DYSFUNCTION; NAUSEA; OPEN STUDY; RASH; RATING SCALE; SCORING SYSTEM; SEIZURE; SOCIAL INTERACTION; SOMNOLENCE; THIRST; TITRIMETRY; TREATMENT OUTCOME;

EID: 0041418151     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-5050(03)00117-3     Document Type: Article

References (49)

1. Steffenburg U, Hagberg G, Viggedal G, et al. Active epilepsy in mentally retarded children. I. Prevalence and additional neuroimpairments. Acta Paediatr 1995:1147-52.
2. Coulter DL. Comprehensive management of epilepsy in persons with mental retardation. Epilepsia 1997;38(Suppl. 4):S24-31.
3. Sunder TR. Meeting the challenge of epilepsy in persons with multiple handicaps. J Child Neurol 1997;12(Suppl. 1):S38-43.
4. Braddock D, Hemp R, Bachelder L, et al. The state of states in developmental disabilities. 4th ed. Washington, DC: American Association of Mental Retardation; 1995.
5. Pellock JM, Morton LD. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Dis 2000;6:309-23.
6. Alvarez N, Besag F, Iivanainen M. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Dis Res 1998;42(Suppl. 1):1-15.
7. Deb S. Mental disorder in adults with mental retardation and epilepsy. Comp Psychol 1997;3:179-84.
8. Coulter DL. Epilepsy and mental retardation: an overview. Am J Ment Retard 1993;98(Suppl.):1-11.
9. Jawad S, Richens A, Goodwin G, et al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
10. Sander JWAS, Patsalos PN, Oxley JR, et al. A randomized, double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
11. Loiseau P, Yuen AWC, Duche B, et al. A randomized double-blind crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7: 136-45.
12. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-53.
13. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
14. Messenheimer JA, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994;35:1113-21.
15. Matsuo F. Lamotrigine. Epilepsia 1999;40(Suppl. 5):S30-6.
16. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-25.
17. Brodie MJ, Richens A, Yuen AWC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
18. Steiner TJ, Dellaportas CI, Findley LJ. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
19. Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999;21:303-6.
20. Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1998;337:1807-12.
21. Messenheimer JA, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998;18:281-96.
22. Uvebrant P, Bauzien PR. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9.
23. Frank LM, Enlow T, Holmes GL, et al. Lamictal monotherapy for typical absence seizures in children. Epilepsia 1999; 40:973-9.
24. Besag RMC, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-7.
25. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
26. Battino D, Buti D, Croci D, et al. Lamotrigine in resistant childhood epilepsy. Neuropediatrics 1993;24:332-6.
27. Herranz JL, Argeaga R, Armijo JA. Three-year efficacy and tolerability of add-on lamotrigine in treatment-resistant epileptic children. Clin Drug Invest 1996;11:214-23.
28. Farrell K, Connolly MB, Munn R, et al. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol 1997;16:201-5.
29. Eriksson A-S, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501.
30. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992;32:305-7.
31. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51.
32. Veggiotti P, Cieuta C, Rey E, et al. Lamotrigine in infantile spasms. Lancet 1994;344:1375-6.
33. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 1993;24:339-40.
34. Stenbom Y, Tonnby B, Hagberg B. Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur Child Adolesc Psychiatry 1998;7:49-52.
35. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
36. Marciani MG, Stanzione P, Mattia D, et al. Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 1998;21:41-7.
37. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001;2:28-36.
38. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
39. Coppola G, Pascotto A. Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. Brain Dev 1997;19:398-402.
40. Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995;4:233-6.
41. Huber B, May T, Seidel M. Lamotrigine in multi-handicapped, therapy-resistant epileptic patients. Clin Drug Invest 1998;16:263-77.
42. Gidal BE, Walker JK, Lott RS, et al. Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. Seizure 2000;9:131-6.
43. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1989;30:389-399.
44. Diagnostic and statistical manual of mental disorders, 4th ed., revised. Washington, DC: American Psychiatric Association; 1994.
45. Aman MG, Singh NN, Turbott SH. Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. Am J Ment Defic 1987;92:237-40.
46. Marshburn EC, Aman MG. Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Dev Disord 1992;22:357-73.
47. Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:522-7.
48. Ettinger AB, Weisbrot DM, Saracco J, et al. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
49. Mirza WU, Credeur LJ, Penry JK. Results of antiepileptic drug reduction in patients with multiple handicaps and epilepsy. Drug Invest 1993;5:320-6.